Wild G, Watkins J, Ward A M, Hughes P, Hume A, Rowell N R
Department of Immunology, Royal Hallamshire Hospital, Sheffield, UK.
J Clin Lab Immunol. 1990 Jan;31(1):39-41.
The use of a synthetic protease inhibitor, nafamstat mesilate, has enabled reliable estimations of in vivo complement activation to be made in patients with systemic sclerosis. Elevations of C3a and C4a anaphylatoxins were found in 2 and 24 out of 30 patients respectively, indicating that complement activation, predominantly by the classical pathway, is a common occurrence in the disease, even though complement C3 and C4 levels were within the reference range.
使用合成蛋白酶抑制剂甲磺酸萘莫司他，已能够在系统性硬化症患者中对体内补体激活进行可靠评估。在30例患者中，分别有2例和24例出现C3a和C4a过敏毒素升高，这表明补体激活（主要通过经典途径）在该疾病中很常见，尽管补体C3和C4水平在参考范围内。
